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A B S T R A C T
Objectives: In the pre-azole era, central nervous system (CNS) infections with Aspergillus had a dismal
outcome. Survival improved with voriconazole but CNS infections caused by azole-resistant Aspergillus
fumigatus preclude its use. Intravenous liposomal-amphotericin B (L-AmB) is the preferred treatment
option for azole-resistant CNS infections but has suboptimal brain concentrations.
Methods: We describe three patients with biopsy-proven CNS aspergillosis where intraventricular L-AmB
was added to systemic therapy. Two patients with azole-resistant aspergillosis and one patient with
azole-susceptible CNS aspergillosis were treated with intraventricular L-AmB at a dose of 1 mg weekly.
Results: We describe three patients successfully treated with a combination of intravenous and
intraventricular L-AmB. All three patients survived but one patient developed serious headaches, most
likely not related to this treatment.
Conclusions: Intraventricular L-AmB may have a role in the treatment of therapy-refractory CNS
aspergillosis when added to systemic therapy.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Few cases of central nervous system (CNS) aspergillosis caused
by azole-resistant Aspergillus fumigatus (ARAF) have been reported,
and almost all of those reported had a fatal outcome [1]. Most
patients were treated with combination antifungal therapy.
Cerebral infections caused by ARAF almost always have a dismal
prognosis. Unfortunately, there are no antifungals available that
have activity against ARAF and adequately penetrate the brain.* Corresponding author at: Department of Internal Medicine, Section of
Infectious Diseases, Erasmus University Medical Center, Room Na-21, P.O.
Box 2040, 3000 CA Rotterdam, Netherlands.
E-mail address: a.schauwvlieghe@erasmusmc.nl (A.F.A.D. Schauwvlieghe).
http://dx.doi.org/10.1016/j.jgar.2020.03.016
2213-7165/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Soc
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Therefore, we added intraventricular liposomal-amphotericin B (L-
AmB) to systemic therapy in three patients. In this study, we




An 18-year-old woman with common acute lymphatic leukae-
mia (ALL) receiving remission induction chemotherapy was
diagnosed with a probable invasive pulmonary aspergillosis
(IPA). Combination therapy with intravenous (i.v.) voriconazole
and L-AmB (3 mg/kg QD) was started. Serum galactomannan was
positive (Optical Density [OD] 2.8) and sputum grew an ARAF withiety for Antimicrobial Chemotherapy. This is an open access article under the CC BY-
Fig. 1. MRI showing multiple nodular lesions. (A) Patient 1. (B) Patient 2. (C) Brain biopsy shows septated hyphae with dichotomous branching at sharp angles using a Gomori
methenamine silver stain.
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the right arm and leg and right facial nerve paralysis were
observed. Brain MRI showed multiple lesions (Fig. 1A) and a brain
biopsy demonstrated hyphae compatible with Aspergillus (Fig. 1C).
L-AmB dose was increased to 10 mg/kg and voriconazole (8 mg/kg
BID) was replaced by posaconazole and dosed at 300 mg BID to
achieve serum trough concentrations >3 mg/L with the hope of
achieving therapeutic brain tissue levels. Posaconazole trough
concentrations of 5.2 and 6.0 mg/L were documented. Follow-up
MRI 15 days after the initiation of therapy showed increased
perilesional oedema. During the following 5 months the patient
was treated with oral posaconazole 300 mg BID with i.v. L-AmB
daily at 5 mg/kg. Six months after diagnosis posaconazole was
stopped as cerebral lesions and perilesional oedema had decreased
and the arm and leg paresis and facial nerve palsy had improved.
Chemotherapy was reinitiated and another 3 months later L-AmB
was discontinued. At that time the lesions on brain MRI had
decreased in size but had not disappeared completely. Unfortu-
nately, 6 months later the patient was admitted for an epileptic
seizure. MRI showed increase in size and oedema around one of the
seven lesions. Combination treatment with i.v. L-AmB (5 mg/kg
QD) and posaconazole (300 mg BID) was reinitiated and was
combined with intraventricular weekly administration of L-AmB
(1 mg/week). The patient was discharged with outpatient therapy
with i.v. L-AmB, oral posaconazole and once-weekly intraventric-
ular L-AmB using an Ommaya reservoir that was placed for this
purpose. The intraventricular L-AmB therapy was well tolerated
and continued for 4 months. The MRI remained essentially
unchanged in these 4 months. The patient was able to walk and
cycle independently but has unilateral hand motor dysfunction as
the only sequela.
2.2. Case 2
A 13-year-old patient with iron overload as a result of multiple
transfusions for beta-thalassaemia was diagnosed with a probable
invasive pulmonary and multifocal cerebral aspergillosis 8 months
after allogeneic stem cell transplantation (Fig. 1B). An ARAF was
cultured from bronchoalveolar lavage (BAL) fluid. Galactomannan
in cerebrospinal fluid (CSF) was positive (OD 1.3). Voriconazole(8 mg/kg BID i.v.) and L-AmB (6 mg/kg) were started. Ten days later
an epileptic seizure occurred. MRI showed increased size of the
brain lesions and again an ARAF grew from a brain biopsy (Table 1).
An Ommaya reservoir was placed for the intraventricular
administration of L-AmB as well as caspofungin (for details on
dosing see Table 1). Also, i.v. caspofungin (70 mg QD) and
flucytosine (25 mg/kg QID) were initiated. With this intervention,
the patient improved and lesions decreased in size. Weekly
intraventricular administration of L-AmB was continued for 10
weeks and intraventricular caspofungin was continued for 6
months. Systemic therapy with flucytosine, L-AmB and caspofun-
gin was discontinued after 2, 6 and 6 months, respectively. No
further improvement of the remaining brain lesions was observed
after 6 months.
Several years later the patient developed disabling headache.
On imaging the skull and dura mater diameter had thickened
significantly. A dura biopsy did not lead to a conclusive diagnosis.
At the last follow-up 9 years post-allogeneic transplant the
complaints of severe headaches had disappeared but spasticity,
occasional epileptic seizures and frontal lobe syndrome had led to
severe disability.
2.3. Case 3
A 15-year-old girl with common ALL developed aphasia 23 days
after chemotherapy initiation. MRI showed one lesion in the left
frontal lobe and one lesion in the temporal lobe. A chest computed
tomography (CT) showed nodular lesions. BAL sampling was
performed. Galactomannan (OD 4.5) was positive and voricona-
zole-susceptible A. fumigatus was cultured (voriconazole MIC
0.5 mg/L). Treatment with voriconazole (4 mg/kg) and L-AmB
(5 mg/kg) was initiated and L-AmB stopped on day 16 when
voriconazole drug levels were therapeutic. Despite voriconazole
serum levels between 3 and 12 mg/L, a follow-up MRI 3 weeks into
therapy showed that lesions had increased in size. L-AmB i.v. was
reinitiated and weekly intraventricular administration of L-AmB
1 mg was started via a Rickham reservoir while voriconazole was
continued also. Follow-up brain MRIs and lung CT at 1 and 2
months into this therapy showed a decrease in the size of the brain
lesions and no increase in lung lesions. A lung biopsy confirmed an
Table 1
Clinical and epidemiological characteristics of patients with cerebral azole-resistant invasive aspergillosis.
Factors Patient 1 Patient 2 Patient 3
Sex, age F, 18 F, 16 F,15
Underlying disease ALL Thalassaemia, allogeneic SCT ALL
Classification IPA (EORTC/
MSG)
Biopsy proven Biopsy proven Biopsy proven (brain and lung)
Culture positive sample Sputum, brain biopsy BAL, brain biopsy BAL
MIC voriconazole 8 16 0.5
MIC posaconazole 2 0.5 0.063
MIC itraconazole >16 16 0.25
MIC isavuconazole – – 0.5
GM value blood 1.3 0.9 0.4
GM value CSF 0.5 1.30 0.5
GM value BAL 2.8 0.36 4.5
Biopsy brain Positive Positive Positive
Treatment regimen (day
after diagnosis)
1. Voriconazole + L-AmB i.v. (3 mg/kg)
(d0–d5)
2. Posaconazole + L-AmB i.v. (10 mg/kg)
(d5–d26)
3. Posaconazole + L-AmB i.v. (3 mg/kg) + IT
L-AmBa (d26–d191)
4. L-AmB 5 mg/kg 3/week (d191–d251)
5. Treatment re-initiation L-AmB i.v. + ITa
(d386–d515)
1. L-Amb i.v. + voriconazole (6 mg/kg) (d0–d10)
2. L-AmB i.v. + caspofungin i.v. (d10–d13)
3. L-AmB i.v. + caspofungin i.v./ITb (d13–d24)
4. L-AmB i.v. and ITa + caspofungin i.v. and ITb
(d24–d32)
5. L-AmB i.v. and ITa + caspofungin i.v. and
ITb + flucytosine i.v. (d32–d97)
6. L-AmB i.v. + caspofungin i.v. and
ITb + flucytosine i.v. (d97–d201)
1. Voriconazole + L-AmB i.v. (d0–d10)
2. Voriconazole (d11–d20)
3. Voriconazole + L-AmB 3 mg/kg i.v./weekly
IT (d21–d109)
4. Voriconazole (d110–d149)
5. Voriconazole + L-AmB 3 mg/kg i.v./weekly
ITa (d149–d176)
6. Isavuconazole + L-AmB 3 mg/kg i.v. and
weekly IT (d176–d227)
7. Isavuconazole + L-AmB weekly ITa
(d228–d348)
8. Isavuconazole (d349–XXX)
a Intraventricular/intrathecal L-AmB was given at a dose of 1 mg weekly.
b Caspofungin IT 1 mg QD for 2 weeks, 1 mg 3/week for 1 month and 3/week 0.5 mg thereafter.ALL, acute lymphatic leukaemia; BAL, bronchoalveolar lavage; CSF,
cerebrospinal fluid; EORTC/MSG, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) host factor; F, female; IPA, invasive pulmonary aspergillosis; IT, intrathecal/intraventricular; i.v.,
intravenous; L-AmB, liposomal amphotericin B; MIC, minimum inhibitory concentration; GM, galactomannan; SCT, stem cell transplantation.
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therapy all infections sites improved, as well as the neurological
disabilities of the patient. After 3 months of combination therapy, a
step-down to voriconazole monotherapy was made. During the
following 6 weeks voriconazole levels were suboptimal (range 0.3–
2.6 mg/L) and unfortunately, 6 weeks later dysarthria developed
and an MRI showed that the lesions had increased in size. A brain
biopsy confirmed the Aspergillus infection of the brain and i.v. and
intraventricular L-AmB was reinitiated. Administration of i.v. L-
AmB was stopped after 2 months but intraventricular continued
for 8 months, whereas voriconazole was switched to isavuconazole
for liver enzyme elevations. Eventually, follow-up imaging of the
lungs and brain showed a good response to therapy. The patient is
doing well and has been successfully treated for ALL. During ALL
therapy, the patient received isavuconazole as secondary antifun-
gal prophylaxis.
3. Discussion
We describe two cases of ARAF and one case with azole-
susceptible CNS aspergillosis treated with intraventricular L-AmB.
Brain infections with Aspergillus have a high mortality and
survivors are left with at least some neurological deficit [2].
Although voriconazole improved the chances of survival, ARAF
now turns back the clock to the amphotericin-B era.
Over the last 10 years, azole resistance has become an
important emerging problem and is associated with very high
mortality [3–6]. When voriconazole resistance is documented in a
patient infected with a cerebral Aspergillus infection, treatment
becomes very difficult. Indeed, few other systemic antifungal
agents have been shown to penetrate the brain. Furthermore, the
therapeutic effect of new drugs is still unknown [7,8]. Pharmaco-
kinetic and pharmacodynamic animal data suggest that compared
with other formulations of amphotericin-B, L-AmB results in the
highest brain tissue concentrations of amphotericin-B and it waseffective as therapy in a mouse model of candida encephalitis [9].
Therefore, it is regarded as the preferred second-line therapy for
cerebral fungal infections but should, at least initially, be dosed at
5–10 mg/kg to achieve therapeutic brain tissue concentrations
quickly [1,10]. For azole-resistant CNS infection, L-AmB can be
combined with a second drug but itraconazole, posaconazole and
echinocandins do not lead to adequate drug concentrations in CSF
or brain tissue with standard dosing regimens [1]. Furthermore, it
seems that combination therapy does not lead to synergistic
treatment effect in vitro against ARAF isolates [11]. To improve CSF
and brain penetration, higher systemic exposure may be aimed for
to subsequently reach higher CSF and brain concentrations that can
exert a pharmacological effect even in the setting where pathogen
susceptibility is reduced. Furthermore, a damaged blood–brain
barrier, which is present in patients with an angio-invasive
Aspergillus infection will likely improve the penetration of selected
drugs. With this in mind, we combined posaconazole with L-AmB
in the first case [12]. Ultimately, we decided to administer L-AmB
directly into the CSF space also. The administration was well
tolerated with no subjective side effects. Contrary to the first and
third case, we observed long-term complications in the second
case. We argue that these side effects are probably the result of
chronic inflammation and scarring during and after the infection
rather than L-AmB or caspofungin-mediated toxicity although we
cannot exclude with certainty the possibility that local combina-
tion of drug therapy contributed to these side effects.
Current guidelines do not recommend the use of intraventric-
ular administration of antifungals owing to the risk of important
adverse events (e.g. chemical meningitis and seizures) [13].
Historically, intrathecal/intraventricular administration of conven-
tional AmB deoxycholate has been and is still being used to treat
patients with coccidioidal meningitis. The side effects of intrathe-
cal/intraventricular administration of AmB deoxycholate make it
difficult to use and only low doses of typically 0.1 mg are used after
which the dose is slowly increased up to 1.0 mg [14]. The reported
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L-AmB instead. Based on a theoretical total CSF volume of ca. 100–
150 mL in our patients, the administration of 1 mg of L-AmB would
result in a peak CSF concentration of L-AmB of 10 mg/mL which is
comparable to the peak plasma concentrations after systemic
administration by Groll et al. [9]. Distribution kinetics as well as
clearance mechanism were unknown so we had no knowledge on
possible accumulation, hence we started with a presumed safe
dose. In case 1 we tried to measure L-AmB in retrospect on residual
CSF fluid but no L-AmB could be detected (limit of detection:
0.5 mg/L). In hindsight we argue that the clearance of L-AmB is
much more rapid than initially expected. This is explained by the
fact that 500 mL of CSF is produced and reabsorbed each day and
helps with clearing L-AmB. Both the dose and frequency of once-
weekly intraventricular administration of 1 mg L-AmB might thus
be suboptimal and a higher dose as well as a more frequent
administration may be preferred for future patients. Intrathecal/
intraventricular L-AmB at a higher dose (10 mg per administration)
for 7 consecutive days was shown to be well tolerated in 18
patients with cryptococcal meningitis [15]. Although the exact role
of intrathecal/intraventricular L-AmB remains to be defined in
patients with an Aspergillus infection of the CNS, we propose to
initiate intrathecal/intraventricular L-AmB as soon as voriconazole
resistance is documented at a dose of 5 mg and preferably twice
weekly. If available, L-AmB CSF concentration monitoring may
guide dosing after the first dose.
Finally, whether local therapy needs to be given in conjunction
with systemic therapy is unknown. The benefit of combination
therapy may be a more favourable ratio of plasma/brain concen-
trations and perhaps a longer detainment of adequate CSF/brain
concentrations.
Case series like ours have several limitations. In particular, all
three patients received systemic treatment also. Therefore, the
exact contribution of the intraventricular L-AmB administration
cannot be defined. However, it is very unlikely that prospective
clinical studies will ever be performed to find the best possible
treatment option for very rare infections like CNS aspergillosis.
Therefore, treatment should be based on in vitro and animal data
and eventually the experience described in case reports and case
series can be helpful as well.
In conclusion, three patients with a CNS infection with A.
fumigatus were treated with combination antifungal therapy that
included intraventricular L-AmB. All three survived but one patient
was left with severe sequelae.
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